EMA’s AI Principles Intended To Be ‘Flexible & Long Lasting’

There is “a lot of flexibility” in the European Medicines Agency’s reflection paper on the use of artificial intelligence during drug development, which is principles-driven rather than setting rigid recommendations, says the agency’s Florian Lasch.

Florian Lasch speaking at the TOPRA Symposium 2024
Florian Lasch speaking at the TOPRA Symposium 2024 • Source: Pink Sheet

The European Medicines Agency recently finalized a reflection paper on the use of artificial intelligence (AI) during the lifecycle of medicinal products to help manufacturers use AI in a safe and effective way.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Agency Leadership